Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida, Takeshi Okanoue & Yoshito Itoh. (2018) Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes, Metabolic Syndrome and Obesity 11, pages 835-843.
Read now
Read now
Articles from other publishers (9)
Dan-dan Li, Yang Yang, Zi-yi Gao, Li-hua Zhao, Xue Yang, Feng Xu, Chao Yu, Xiu-lin Zhang, Xue-qin Wang, Li-hua Wang & Jian-bin Su. (2022) Sedentary lifestyle and body composition in type 2 diabetes. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Lan Cheng, Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Weiqing Lin & Xiaohe Wu. (2021) Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Scientific Reports 11:1.
Crossref
Crossref
Alvaro Pano-Rodriguez, Jose Vicente Beltran-Garrido, Vicenç Hernandez-Gonzalez & Joaquim Reverter-Masia. (2020) Effects of Whole Body Electromyostimulation on Physical Fitness and Health in Postmenopausal Women: A Study Protocol for a Randomized Controlled Trial. Frontiers in Public Health 8.
Crossref
Crossref
Riobaldo M. R. Cintra, Alexandre A. S. Soares, Ikaro Breder, Daniel B. Munhoz, Joaquim Barreto, Sheila T. Kimura-Medorima, Pamela Cavalcante, Renata Zanchetta, Jessica Cunha Breder, Camila Moreira, Vitor W. Virginio, Isabella Bonilha, Jose Carlos Lima-Junior, Otavio R. Coelho-Filho, Vaneza L. W. Wolf, Gil Guerra-Junior, Daniela C. Oliveira, Rodrigo Haeitmann, Vicente H. R. Fernandes, Wilson Nadruz, Fernando R. P. Chaves, Carlos E. L. Arieta, Thiago Quinaglia & Andrei C. Sposito. (2019) Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. Diabetology & Metabolic Syndrome 11:1.
Crossref
Crossref
Pankaj Aneja, Gaurav Bhalla, Neeti Parvesh, Kunal Aneja & Kashish Aneja. (2019) Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study. Indian Journal of Endocrinology and Metabolism 23:3, pages 307.
Crossref
Crossref
Manash P Baruah & Sanjay Kalra. (2019) Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study. European Endocrinology 15:2, pages 113.
Crossref
Crossref
Mahmoud El-Daly, Vivek Krishna Pulakazhi Venu, Mahmoud Saifeddine, Koichiro Mihara, Sean Kang, Paul W.M. Fedak, Laurie A. Alston, Simon A. Hirota, Hong Ding, Chris R. Triggle & Morley D. Hollenberg. (2018) Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vascular Pharmacology 109, pages 56-71.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref